In Brief: Meretek
This article was originally published in The Gray Sheet
Executive Summary
Meretek: Begins shipping UBT H. pylori breath test in the U.S. market. The non-invasive test, which is being promoted as a lower-cost alternative to endoscopy with stomach biopsy, uses non-radioactive technology to diagnose active H. pylori. The UBT test gained FDA marketing clearance via a joint 510(k)/new drug application in September ("The Gray Sheet" Sept. 23, I&W-7). FDA required the NDA submission because Pranaetin, a non-radioactive diagnostic drug, is consumed by patients taking the test...
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.